Background
==========

Juvenile idiopathic arthritis (JIA) is a heterogeneous disease, and it's associated with an increased use of various biological agents in recent years.

Aim
===

Evaluate clinical response to current biological agent in JIA patients.

Methods
=======

This is a retrospective study of 109 JIA patients from a tertiary centre (see poster 1). Variables included were: current biological treatment (both the first agent used as the second, third or fourth when it had been switched) and duration of treatment (years with a new agent or since reintroduction of an agent used before) plus physician visual analogue scale (ph-VAS), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) at baseline and at the end of the study. Concomitant therapy with methotrexate (MTX) was also recorded.

Results
=======

Duration of treatment with the current biological agent was 1.2 ± 1 (0.1- 4.9) median 0.8 years. This agent was etanercept (ETA) in 58 cases, adalimumab (ADA) in 16, tocilizumab (TCZ) in 11, anakinra (AK) in 9 and infliximab (IFX) in 2. Thirteen patients were off treatment with biological agents, 12 due to inactive disease and one because of inefficacy.

Concomitant treatment with MTX was observed in 8/58 (14%) patients with ETA, 4/16 (25%) with ADA, 5/11 (46%) with TCZ, 1/2 (50%) with IFX and none with AK. Table [1](#T1){ref-type="table"}.

###### 

Analytical and clinical response to current biological agent

  ----- ----------- ------- ----- ------ ----------- ------- ---- ------ ----------- ------- ---- ------
        Ph-VAS      ESR     CRP                                                                   
        Initial\*   End\*   ۵     p      Initial\*   End\*   ۵    p      Initial\*   End\*   ۵    p
                                                                                                  
  ETA   3.25        0.5     -6    0.00   28          12      -5   0.00   13.2        2.3     -5   0.00
  ADA   2.42        0.4     -3    0.01   17          13      -1   0.26   5.58        1.2     -2   0.06
  AK    5.36        0.00    -3    0.01   62          9       -2   0.02   69.5        2.9     -2   0.03
  TCZ   6.45        0.86    -3    0.01   46          4       -3   0.01   95.6        0.6     -3   0.01
  IFX   4.9         0.00                 47          6                   32.8        0.9          
  ----- ----------- ------- ----- ------ ----------- ------- ---- ------ ----------- ------- ---- ------

\*Values are expressed as mean.

Conclusion
==========

The results indicate that reintroduction of a previously effective biological agent may be successful; besides, switching to a second, third or even fourth biological agent in those patients whose disease remains active, can be effective as well.
